Navigation Links
Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Date:3/11/2008

the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Michael W. Rogers
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
2. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Announces Allergan as New Partner for SANCTURA Brand
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
8. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)..., part of Life Technologies Corporation (NASDAQ:LI...h and discovery solutions, today announced that it... the SOLiD™ System, has been named the Life ...entist, a leading scientific publication focused o...ement of the first-ever Life Science Innovation of...
(Date:12/3/2008)...nd secondhand smoke, an estimated ten percent of p...f a developing baby to harmful cigarette byproduct...000 newborns each year and poses a significant hea...s kind, a team of researchers has completed a glob... better understand the fetal health risks from smo...
(Date:12/3/2008)...FirstCall/ -- GlaxoSmithKline,(LSE/NYSE: GSK ) ...ating to a,pending lawsuit in the previously anno...ding shares of common stock of Genelabs Technologi...n cash without interest and less any,required wit...completion of the tender offer that there not be,...
(Date:12/3/2008)...-- Cellectricon, a leading,provider of screening ...,signing of a collaborative agreement with The Aut...s of advanced automated systems for cell culture, ...pplications. Under the agreement,TAP will co-deve...ectricon,s,next generation high throughput ion ch...
Breaking Biology Technology: Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 4 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 5Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 2Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 3
...ely following the progress of the Health Insuranc...electronic health records for the last eight month... dentist with a small healthcare business, I have ...all a "stakeholder" in this exciting and promising...re important than my job, I am a husband and fathe...
...- BellBrook Labs has been awarded two federal gran...opment of its enzyme screening product. , ,The bio... screening tools for the drug-therapy market, said...l Business Innovation Research (SBIR) awards. Hig...ct millions of biochemical, genetic, or pharmacolo...
...- An education research team at the University of...he MacArthur Foundation to study the impact of d...acy. , ,MacArthur,s total $50 million investment ...cts of the digital revolution and its educational ...actually trying to do, with this grant to us, is e...
...eek in Austin , Dallas , and Boston , getting a...art ups. (Yep, you guessed it, the search for DEMO...h of what I saw was quite impressive. It was also ...lley . , ,Where Silicon Valley is at the apex of ...dership in IT systems management. In Dallas, I fou...
Other Biology Technology:Careful with that electronic health record, Mr. Leavitt 2Careful with that electronic health record, Mr. Leavitt 3Careful with that electronic health record, Mr. Leavitt 4Grants worth $800,000 help BellBrook Labs develop products 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3What makes Silicon Valley so different? 2What makes Silicon Valley so different? 3What makes Silicon Valley so different? 4
(Date:12/4/2008)...en want younger women, often touting their intelli...earch at Gothenburg University and Oxford Universi...en and women choose partners. , Research in the ...theories about how men and women choose their part... place more emphasis on attractive appearance, whe...
(Date:12/3/2008)...nes, deputy executive director of the Internationa...tlook 2008" Dec. 9 at Rice University,s Baker Inst...ch questions as: Is the world facing a supply crun...at type of post-Kyoto policy framework might stabi... and what impact might such a policy framework hav...
(Date:12/3/2008)...re. December 3, 2008. The first 5-year forest inve... is now available to the public: Oregon,s Forest R...d Analysis Report. , Here are some key findings ... 30 million acres; about half of Oregon,s total la...ng converted to other uses particularly near urban...
(Date:12/3/2008)...-- A Duke University study suggests that evolution... the dogs depend on an energy-efficient style of f...eir prey, cats seem to have evolved a profoundly i...e or bird in slow motion. , "It is usually assum...said Daniel Schmitt, a Duke associate professor of...
Breaking Biology News(10 mins):Myth about 'dirty old men' supported by science 2'World Energy Outlook' to be presented at Rice University Dec. 9 2Forest inventories in Oregon include more than trees 2Forest inventories in Oregon include more than trees 3Dogs chase efficiently, but cats skulk counterintuitively 2Some Iraq War Vets Suffer Breathing Problems 19978 1Some Iraq War Vets Suffer Breathing Problems 19978 2Some Iraq War Vets Suffer Breathing Problems 19978 3Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 1Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Low intensity case management cuts COPD related hospital visits in half 19966 1Low intensity case management cuts COPD related hospital visits in half 19966 2
...omparison of equipment that can analyze the expres...etic "fingerprint," suggests these different micro...t. , Published in the May 2005 issue of Nature Me... of information generated by these systems might a...systems are used by many different laboratories. ,...
...he University of Liverpool have discovered how the...f Europeans resistant to HIV. Scientists have know...etic mutation (known as CCR5-delta32) that prevent...system but have been unable to account for the hig... low levels in areas bordering the Mediterranean. ...
...of North Carolina at Chapel Hill is one of five cl...e National Institutes of Health to study why good ...ring the next seven years, the Drug-Induced Liver ...have suffered severe liver injury caused by prescr...al supplements, alternative medicines and herbals....
... microarray analyses result in many differentially...for the biological process of interest. In order t...publications from MEDLINE were identified in which... with specific keywords were co-mentioned. , MEDLI... keywords were generated and validated. PubMed IDs...
Other Biology News:Different microarray systems more alike than previously thought 2Different microarray systems more alike than previously thought 3First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes 2UNC launches study of liver injury caused by drugs 2
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein
MOUSE ANTI BOVINE TROPONIN I
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG
Normal donkey serum collected from healthy normal donkeys.
Biology Products: